Environmental exposome study for prostate cancer in elderly men from Western China: preliminary findings from a case-control study in the WeEndPd cohort.

Abstract

To investigate the association between exposure to specific endocrine-disrupting chemicals (EDCs), air pollutants and the risk of localised prostate cancer (PCa) and to evaluate the combined effect of mixed EDC exposures. A case-control study. Secondary care; a single tertiary hospital in Western China. A total of 580 patients with histologically confirmed localised PCa who underwent radical prostatectomy between May 2021 and June 2023 were included as cases. They were matched 1:2 with 1160 cancer-free controls from the same cohort on age (±5 years) and date of biological sample collection. Key exclusion criteria were a history of other malignancies, androgen deprivation therapy prior to surgery or acute urinary infection. The primary outcome was the odds of PCa associated with individual and mixed exposures. Primary exposures were urinary concentrations of nine bisphenols (BPs) and nine phthalate metabolites (quantified via high-performance liquid chromatography-tandem mass spectrometry) and estimated ambient air pollution exposure (sulphur dioxide (SO₂) and PM_₂.₅) based on geocoded residential addresses. A total of 580 cases and 1160 controls were included in the final analysis. Exposure to the highest quartile of sulphur dioxide (SO₂) over 5 years (9.37-28.79 µg/m³) was significantly associated with PCa, yielding an OR of 1.65 (95% CI 1.08 to 2.72; p<0.001) compared with the lowest quartile (3.61-6.89 µg/m³). Urinary concentrations of multiple phthalate metabolites (MECPP, MEHHP and MEHP) and BPs (bisphenol A (BPA) and BPZ) were significantly higher in cases (all p<0.05). Weighted quantile sum (WQS) regression analysis demonstrated a significant positive association between the mixture of EDCs and PCa risk (WQS OR=1.26, 95% CI 1.20 to 1.33; p<0.001). Exposure to SO₂ and specific EDCs (both individually and as a mixture) is significantly associated with localised PCa. ChiCTR1900024623.